Luminex has secured clearance in the U.S. and Europe for its xTAG CYP2D6 tool, a genotyping assay kit used to help predict patients' responses to specific drugs and allow doctors to personalize treatments. The company also applied for FDA review of a kit intended to analyze the effects of medications used to treat ulcers and other conditions.

Related Summaries